Jacqueline Todd, DO
Family Medicine · Largo, FLNPI 1487815130
Payments from drug & device makers
Across 155 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$493
- Novo Nordisk$381
- AbbVie$333
- Lilly USA, LLC$288
- GSK$282
- Amgen$256
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,23099%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $493 |
| Novo Nordisk | 20 | $381 |
| AbbVie(2 entities) | 16 | $333 |
| Lilly USA, LLC | 15 | $288 |
| GSK | 11 | $282 |
| Amgen | 15 | $256 |
| Pfizer | 11 | $184 |
| Eisai Inc. | 4 | $130 |
| Novartis | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Phathom Pharmaceuticals, Inc. | 3 | $84 |
| Madrigal Pharmaceuticals | 2 | $78 |
| Abbott | 4 | $78 |
| Astellas Pharma US Inc | 4 | $64 |
| Exact Sciences | 3 | $63 |
| Merck | 3 | $55 |
| Amarin Pharma, Inc. | 3 | $55 |
| Johnson & Johnson | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Almatica Pharma LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $31 |
| Insmed, Inc. | 1 | $25 |
| Braintree Laboratories, Inc. | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,249 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $80,363 |
| ProliaDenosumab | 31 | $55,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $44,677 |
| OzempicSemaglutide | 32 | $38,341 |
| XareltoRivaroxaban | 32 | $35,346 |
| JanuviaSitagliptin Phosphate | 18 | $28,919 |
| Bydureon BciseExenatide Microspheres | 27 | $28,192 |
| TrulicityDulaglutide | 22 | $26,625 |
| MyrbetriqMirabegron | 27 | $22,894 |
| FarxigaDapagliflozin Propanediol | 19 | $22,373 |
| JardianceEmpagliflozin | 15 | $21,838 |
| CreonLipase/Protease/Amylase | 11 | $20,652 |
| Repatha SureclickEvolocumab | 25 | $18,694 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $14,149 |
| Atorvastatin Calcium | 541 | $6,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $80,36371 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $282 | $58,82654 claims |
| AmgenProlia | $256 | $55,13931 claims |
| Novo NordiskOzempic | $381 | $38,34132 claims |
| Johnson & JohnsonXarelto | $46 | $35,34632 claims |
| MerckJanuvia | $55 | $28,91918 claims |
| AstraZenecaFarxiga, Symbicort | $493 | $27,60237 claims |
| Lilly USA, LLCTrulicity | $288 | $26,62522 claims |
| AbbVieCreon, Synthroid | $333 | $23,80737 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $22,89427 claims |
| Almatica Pharma LLCSertraline Hcl | $33 | $1,788165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Largo
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.